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Background: Undifferentiated pleomorphic sarcoma (UPS) is a heterogeneous tumor group, and little is known
about molecular target therapy for UPS. Heat shock protein 90 (HSP90) is an expressed chaperone that refolds
certain denatured proteins under stress conditions. One of these proteins is Akt. The disruption of Akt signaling
plays an important role in tumor progression. The present study’s purpose was to analyze the HSP90 expression,
Akt/mTOR pathway activation and the correlation between HSP90 expression and its pathway activation in UPS.
Methods: The status of HSP90 and the profiles of the Akt/ mTOR pathway were assessed by immunohistochemistry
in 79 samples of UPS, and these data were compared with clinicopathological and histopathological findings. The
expressions of indicated proteins were assessed by Western blotting in five frozen samples. After treating UPS cells
with the HSP90 inhibitor, we assessed the antitumor effect of the inhibitor.
Results: Immunohistochemically, phosphorylated Akt (p-Akt), p-mTOR, p-S6RP and p-4EBP were positive in 57.3,
51.9, 54.5 and 57.1 % of the UPS samples, respectively. The expressions of those phosphorylated proteins were
correlated with each other. HSP90 expression was elevated in 56.4 % of the samples and was correlated with p-Akt,
p-mTOR and p-S6RP. The immunohistochemical results were confirmed by Western blotting. The HSP90 inhibitor
led to decreased viability and invasiveness of the cells and inactivated the AKT/mTOR pathway in vitro.
Conclusion: Elevated expression of HSP90 is a poor-prognosis factor and is involved in the activation of the
Akt/mTOR pathway in UPS. HSP90 inhibition is a potential treatment option for UPS.
Keywords: Undifferentiated pleomorphic sarcoma, Heat shock protein 90, Akt/mammalian target of rapamycin
pathway, Mitogen-activated protein kinase pathway, PhosphorylationBackground
Undifferentiated pleomorphic sarcoma (UPS) showing
no identifiable line of differentiation is a heterogeneous
tumor group as defined by the World Health
Organization (WHO) classification [1]. Radiation-
induced tumor genesis has also been identified. Heat
shock proteins (HSPs) are chaperones responsible for
protein folding in normal cells [2], and HSP90, a* Correspondence: oda@surgpath.med.kyushu-u.ac.jp
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proteins under stress conditions and activates these pro-
teins, which are called “client proteins” [3]. The proteins
include the growth-stimulating proteins and kinases that
support malignant transformation [4].
One of the important client proteins is Akt [3], a
serine/threonine kinase activated by phosphoinositide 3-
kinase (PI3K). Akt activates the downstream mammalian
target of rapamycin (mTOR). The Akt/mTOR pathway
plays diverse roles in the normal oncogenic process [5].
In addition to HSP90, another molecule involved in the
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function, and the loss of PTEN activates the Akt/
mTOR pathway. Several studies have demonstrated
the activation of the Akt/mTOR pathway in various
sarcomas [7–9]. To our knowledge, there is no report
of an analysis of the roles of HSP90 and the Akt/
mTOR pathway in UPS.
Another signaling pathway that involves HSP90 is the
mitogen-activated protein kinase (MAPK) pathway,
which plays a key role in the transduction of extracellu-
lar signals to cellular responses. There is signaling cross-
talk between the AKT/mTOR and MAPK pathways. The
MAPK pathway requires the HSP90-chaperone function
for proper folding and stability [4]. The relationship be-
tween the MAPK pathway and HSP90 in UPS remains
to be clarified.
HSP90 inhibitors are well-known molecular thera-
peutic agents. HSP90 inhibition results in a mechanism-
based change in the expression of specific proteins [10].
In terms of the Akt/mTOR pathway, the inhibition of
HSP90-Akt binding leads to the dephosphorylation and
inactivation of Akt [3]. We postulated that an HSP90 in-
hibitor might be effective against UPS if an elevated ex-
pression of HSP90 is involved in the activation of the
Akt/mTOR and MAPK pathways in UPS.
First, we reclassified tumors that had been diagnosed
as pleomorphic sarcoma (including unclassified/undiffer-
entiated pleomorphic sarcoma). In these reclassified
UPSs, we analyzed the HSP90 expression, Akt/mTOR
pathway activation and the relationship between HSP90
expression and Akt/mTOR pathway activation, and we
investigated the status of the MAPK pathway. The anti-
tumor effect of an HSP90 inhibitor on UPS cell lines
in vitro was also evaluated.
Methods
Patients and materials
We reassessed individual patients’ 157 tumors (150 pri-
mary tumors, 6 recurrent tumors, and 1 metastatic
tumor) that had been diagnosed as pleomorphic sarcoma
at the Department of Anatomic Pathology, Kyushu
University, Fukuoka, Japan between 2000 and 2014,
according to the flow chart provided as Fig. 1.
Radiation-induced sarcomas or secondary sarcomas after
chemotherapy were not included in this study. In each
case, we carefully reviewed the hematoxylin and eosin
(H&E)-stained slides. We also examined 32 cases that
were immunoreactive for CDK4 (Invitrogen, Carlsbad,
CA) or MDM2 (Calbiochem, La Jolla, CA) for MDM2
gene amplification by fluorescence in situ hybridization
(FISH).
After the reclassification, 107 of the 157 tumors were
diagnosed as UPSs. The reassessed diagnosis of UPS was
made according to the WHO 2013 classification [1]. Weexcluded 50 sarcomas, including pleomorphic sarcomas
located in the thoracic/abdominal cavity or the retroper-
itoneum (32 cases), undifferentiated spindle cell sarco-
mas (3 cases), pleomorphic sarcomas with focal myxoid
stroma (8 cases), and undifferentiated pleomorphic sar-
comas with MDM2 gene amplification (7 cases). Follow-
up information was available in 102 tumor cases. The
median follow-up period after surgery was 36 months
(range 3–168 months), excluding the cases of the pa-
tients who had died.
We evaluated the extent of necrosis and mitosis ac-
cording to the French Federation of Cancer Centers
(FNCLCC) grading system [11]. The seventh edition of
the American Joint Committee on Cancer (AJCC) sta-
ging system was applied to each case [12]. The Institu-
tional Review Board at Kyushu University approved this
study (permission code 25–79). Written informed con-
sent for participation in the study was obtained from the
patients or from a parent of pediatric patients.
Cell culture and reagents
The human UPS cell lines FPS-1 and FU-MFH-2 were
cultured in RPMI-1640 medium and Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F-12 [13, 14]. These
media preparations were supplemented with 10 % fetal
bovine serum (FBS) plus penicillin and streptomycin.
The HSP90 inhibitor alvespimycin (17-dimethylami-
noethylamino- 17-demethoxygeldanamycin; 17-DMAG)
was purchased from Seleck Chemicals (Houston, TX)
and diluted in dimethyl sulfoxide (DMSO).
Immunohistochemistry (IHC)
Immunohistochemical staining was performed as de-
scribed [9]. Among the 107 UPSs, 79 formalin-fixed
paraffin-embedded samples (74 primary tumors, 4 recur-
rent tumors, and 1 metastatic tumor) were available for
this IHC analysis. Antigen retrieval was performed by
boiling the slides with 10 mM sodium citrate (pH 6.0) or
Target Retrieval Solution (Dako, Carpinteria, CA). We
used rabbit antibodies for phosphorylated (p) Akt (p-
Akt) (serine 473 [Ser473]; 1:50 dilution), p-mTOR
(Ser2448; 1:100 dilution), p-S6 (Ser235/236; 1:100 dilu-
tion), p-4E-BP1 (threonine 37/46 [Thr37/46]; 1:400 dilu-
tion), p- mitogen-activated protein kinase1/2 (p-MEK1/
2) (Ser217/221; 1:100 dilution), p-extracellular signal-
regulated kinase (p-ERK1/2) (Thr202/Tyr204; 1:400 dilu-
tion), PTEN (1:50 dilution) and HSP90 (1:400 dilution)
(Cell Signaling Technology, Danvers, MA). The mouse
antibody for Ki-67 (MIB-1) (1:100 dilution) (Dako) was
used as the primary antibody.
The results for p-Akt, p-mTOR, p-S6RP, p-4E-BP,
p-MEK1/2, p-ERK1/2 and PTEN were evaluated ac-
cording to the method of Dobashi et al. [15]. When
>10 % of the tumor cells showed nuclear and/or
Fig. 1 Reclassification of “UPS-like” sarcomas to “pure” UPS. We excluded 32 tumors in the body cavity because the tumors could be a
component of a sarcomatoid carcinoma or dedifferentiated liposarcoma (DDLS). Three tumors were reclassified as undifferentiated spindle cell
sarcomas. Eight pleomorphic sarcomas with focal myxoid stroma were also excluded because the difference in the diagnosis between UPS with
focal myxoid component and high-grade myxofibroarcoma (MFS) was ambiguous. Seven undifferentiated pleomorphic sarcomas with MDM2
amplification were excluded because their biological character is similar to that of DDLS. A FISH analysis showed an MDM2 red signal present in a
cluster in a tumor cell nucleus (green: centromere of chromosome 12)
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endothelial cells, the samples were judged as positive.
We also assessed the HSP90 expression as described
by Song et al. [16]. Cases with >5 % nuclear- or
cytoplasmic-positive tumor cells with stronger inten-
sity than the endothelial cells were classified as posi-
tive. The MIB-1 labeling index was defined as the
percentage of immunoreactive cells divided by the
total number of cells in the evaluated area. Five viable
fields from the area of maximal labeling were chosen
for counting. Each section was evaluated independ-
ently by three investigators.
Fluorescence in situ hybridization (FISH)
To rule out dedifferentiated liposarcoma (DDLS), we
examined 32 clinical samples and the UPS cell lines
(FPS-1 and FU-MFH-2) for MDM2 gene amplifica-
tion. Fluorescence in situ hybridization (FISH) using
the MDM2 (TexRed)/CEN1q (FITC) Dual Color FISH
Probe (Abnova, Taipei, Taiwan) was performed on tis-
sue sections. Each formalin-fixed paraffin-embedded
tissue was cut at 4-μm thickness. The deparaffiniza-
tion, pretreatment, and protease digestion procedures
followed the manufacturer’s protocol. The probe cock-
tail labels the human chromosomal region MDM2
with a red signal and the centromeric region of
chromosome 12 (12p11.12 sequences) with a green
signal. We counted the signals under a microscope
(BX53, Olympus, Tokyo) and analyzed them with the
cellSens Standard software (version 1.9; Olympus). Aminimum of 20 nuclei per slide were visualized.
Amplification was defined as >2.0 fluorescent signals
per cell [17].
Western blotting
The Western blot analysis was conducted as described
[18]. Protein was extracted from five available frozen
samples paired with normal muscular tissue and from
the cultured UPS cells after they were treated with
17-DMAG (0.3 μmol/L) for 6, 12 or 24 h. In addition
to the antibodies used for the IHC analysis, the rabbit
antibodies for pan-Akt (C67E7; 1:400 dilution), pan-
mTOR (1:400 dilution), and pan-S6RP (5G10; 1:400
dilution) (Cell Signaling Technology) were used as the
primary antibody. For an internal control, an anti-
glyceraldehyde 3-phosphate dehydrogenase (anti-
GAPDH) (1:5,000 dilution; Santa Cruz Biotechnology,
Santa Cruz, CA) mouse monoclonal antibody was
used. For p-MEK1/2 and p-Erk1/2, the comparison of
protein expression between tumor tissue and normal
muscular tissue was not made because the MAPK
pathway may be activated under a state of periopera-
tive stress in skeletal muscle [19].
The phosphorylation scores were calculated using the
formula reported by Setsu et al. as follows: (p-protein
[tumor]/pan-protein [tumor])/(p-protein [normal]/pan-
protein [normal]) [20]. This formula was applied to Akt,
mTOR and S6RP. The intensities of p-4EBP, PTEN and
HSP90 were compared with that of GAPDH instead of
pan-protein.
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Tumor cells were harvested at 70 % confluence, seeded
at 3 × 103 cells per well in 96-well plates, and incubated
in the medium for 12 h. 17-DMAG was added to each
well at the indicated concentration, and the incubation
was continued for another 48 or 72 h as described by
Mayer et al. [21]. Viability was assessed by performing a
WST-8 assay using the Cell Counting Kit 8 (CCK-8,
Dojindo Molecular Technologies, Kumamoto, Japan) ac-
cording to the manufacturer’s protocol. The absorbance
at 450 nm was measured by a microplate reader (Model
680 Microplate Reader, Bio-Rad Laboratories, Hercules,
CA). The percentage growth was calculated relative
to untreated controls. Each assay was carried out in
triplicate, with results based on three independent
experiments.
Wound-healing assay
A wound-healing assay was conducted using the UPS
cell lines FPS-1 and FU-MFH-2. Confluent cell mono-
layers in 6-well plates were wounded by scraping with a
micropipette tip. The wells were treated with 0.1 nmol/L
of 17-DMAG. The cell motility was assessed by compar-
ing the sizes of the scratches at 0 h and at 12 h with a
microscope (BZ-8000, Keyence, Tokyo). Each assay was
conducted in triplicate and repeated three times.
Matrigel invasion assay
Cell invasiveness was assessed using the 24-well Biocoat
Matrigel invasion chamber (BD Biosciences, San Diego,
CA) according to the manufacturer’s protocol. Cells
(FPS-1 and FU-MFH-2) were detached from culture
plates and resuspended in the upper chamber separated
by an 8-mm pore-size filter at 1 × 105 per chamber in
serum-free media. Outer wells were filled with media
containing 5 % FBS. The chambers were treated with the
0.1 nmol/L of 17-DMAG. The cells were incubated at
37 °C with 5 % carbon dioxide for 24 h, and then non-
invading cells were removed by wiping with a cotton
swab. Invading or migrating cancer cells were fixed to
the lower surface of the transwell membrane with 70 %
ethanol, stained with H&E, and counted in five random
fields at 200× magnification.
The membrane was mounted on a microscope slide,
and migrated cells were counted in five random high-
power fields. Data are expressed as the percentage of
invasion through the Matrigel matrix and membrane
relative to the migration through the control membrane,
according to the manufacturer’s manual.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation values. All parameters were analyzed for their
correlation to one another by using the Fisher exact test.The survival correlations are illustrated with Kaplan-
Meier curves using the cutoff at 15 years, and survival
analyses were performed using the log-rank test. In the
multivariate analysis, a Cox proportional hazards model
was used to examine risk factors picked up in the uni-
variate analysis for clinicopathological parameters and
the immunohistochemical results. In vitro data were an-
alyzed by Student’s t-test. A two-sided p-value <0.05 was
considered significant. The data analyses were conducted
with the JMP statistical software package (version 9.0.2;
SAS Institute, Cary, NC).
Results
The AJCC stage was identified as a poor-prognosis risk
factor based on the clinicopathological findings after
reclassification
After the classification, 107 (102 primary, 4 recurrent,
and 1 metastatic) of the 157 tumors (68 %) were diag-
nosed as UPS. The 107 tumors were located in the ex-
tremities in 65 cases (thigh, 40; upper arm, 11; lower leg,
9; and forearm, 5), in the trunk wall in 31 cases (buttock
13, back 7, shoulder 5, chest wall 4, and abdominal wall
2) and in the head and neck in 11 cases. We excluded a
total of 50 tumors from the study. Thirty-two tumors in
the thoracic/abdominal cavity were excluded because of
the possibility that the tumor could be a component of
sarcomatoid carcinoma or DDLS [22]. Three tumors
were reclassified as undifferentiated spindle cell sarco-
mas, because pleomorphic cells were inconspicuous.
Eight pleomorphic sarcomas with focal myxoid stroma
were also excluded because the difference in the diagno-
sis between UPS with focal myxoid component and
high-grade myxofibrosarcoma (MFS) seemed ambiguous.
Seven of the 32 (21.9 %) undifferentiated pleomorphic
sarcomas with MDM2 amplification were excluded be-
cause their biological character is similar to that of
DDLS [23]. The amplification of the MDM2 gene locus
is illustrated in Fig. 1.
The data of the 102 primary tumors are summarized
in Table 1. Representative H&E staining is shown in
Fig. 2. In the univariate analysis, overall survival (OS)
was significantly related to differences in large (>50 mm)
tumor size, deep location, the existence of metastasis
and tumor necrosis, more frequent mitosis, FNCLCC
grade 3, and high AJCC stage (i.e., III or IV). As for
event-free survival (EFS), the prognostic risk factors
were tumor size >50 mm, deep location, the existence of
tumor necrosis, frequent mitosis with ≥ 20 per 10 high-
power fields (HPF), FNCLCC grade 3, and higher AJCC
stage (IV > III > II). The multivariate analysis demon-
strated that the AJCC stage was a poor-prognosis risk
factor for OS and EFS. Tumor size, the existence of me-
tastasis and tumor necrosis, mitotic activity, and
FNCLCC grade were excluded from this multivariate
Table 1 Clinicopathological parameters and survival analysis in 102 primary UPS tumors
P
Variable Group No. (%) Analyzed groups Overall survival Event-free survival
Sex Male 45 44.1 0.3077 0.1815
Female 57 55.9
Age (17 ~ 93, mean: 62) <62 53 52 0.3714 0.1518
≧62 49 48
Size <5 cm 35 34.3 0.0058a 0.0008a
≧5 cm 56 54.9
N/A 11 10.8
Location Superficial 42 41.2 0.0154a 0.0193a
Deep 54 52.9
NA 6 5.9
Chemotherapy Yes 20 19.6 0.5761 0.9270
No 30 29.4
NA 52 51.0
Surgical margin Positive 18 17.6 0.3069 0.9937
Negative 45 44.1
NA 39 38.3
Metastasis + 28 27.5 <0.0001a <0.0001a
- 74 72.5
Reccurence + 16 15.7 0.9212 <0.0001a
- 86 84.3
Necrosis 0, score 0 58 56.9 Score 0 vs others 0.0011a 0.0101a
<50 %, score 1 31 30.4 Score 1 vs score 2 0.464 0.6221
≧50 %, score 2 13 12.7 Score 2 vs others 0.0344a 0.2112
Mitosis 0–9/10 HPF, score 1 53 52 Score 1 vs others 0.0003a 0.0005a
10–19/10 HPF, score 2 28 27.4 Score 2 vs score 3 0.0291a 0.4872
20≧/10 HPF, score 3 21 20.6 Score 3 vs others <0.0001a 0.0077a
MIB-1 LI <10 % 20 26.7 0.0569 0.0533
≧10 % 50 66.7
NA 5 6.6
FNCLCC 2 64 62.7 <0.0001a 00002a
3 38 37.3
AJCC 7th ed II 59 57.8 Stage II vs others <0.0001a <0.0001a
III 15 14.7 Stage III vs IV 0.0614 <0.0001a
IV 28 27.5
AJCC American Joint Committee on Cancer, FNCLCC French Federation of Cancer Centers, HPF high-power fields, LI labeling index, N/A not available, No. number
of patients. The Fisher exact test or the log-rank test was used if not indicated otherwise
aStatistically significant
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these parameters.
The Akt/mTOR pathway and HSP90 were
immunohistochemically correlated and revealed to be
risk factors for a poor prognosis in UPS
The IHC results for the Akt/mTOR pathway, the
MAPK pathway and HSP90 are illustrated in Fig. 2.The correlation between the IHC results and clinico-
pathological data are summarized in Additional file 1:
Table S1. The positive ratios were as follows: p-Akt,
57.3 %; p-mTOR, 51.9 %; p-S6RP, 54.5 %; p-4EBP,
57.1 %; p-MEK1/2, 48.6 %; p-ERK1/2, 74.0 %; PTEN,
77.3 %; and HSP90, 56.4 %. The cases in which endo-
thelial cells failed to reveal any staining were excluded
from the evaluation: p-Akt, four cases; p-mTOR, two;
Fig. 2 Representative H&E stain (a) and immunohistochemical staining (b–g). Positive stains for p-Akt (b), p-mTOR (c), p-S6RP (d), and p-4EBP (e)
in the Akt/mTOR pathway and p-MEK1/2 (f), and p-Erk1/2 (g) in the MAPK pathway. Decreased expression of PTEN in the tumor cells and
immunostaining of endothelial cells (h). Immunohistochemical staining with different intensities for HSP90 (i). Immunohistochemically nuclear
and/or cytoplasmic staining was judged as positive. Bar: 100 μm
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four; and PTEN, three cases.
The positivities for p-Akt, p-mTOR and p-S6RP and
p-4EBP were significantly correlated with each other
(p < 0.05). The elevated expression of HSP90 showed
significant correlations with the positivities for p-Akt
(p = 0.0003), p-mTOR (p = 0.0223), and p-S6RP (p =
0.0004). The loss of PTEN was not correlated with
the activation of the Akt/mTOR pathway or the elevated
expression of HSP90. The positivities for p-MEK1/2
and p-Erk1/2 were significantly correlated with each
other (p = 0.021). The positivity for p-MEK1/2 was corre-
lated with the elevated expression of HSP90 (p = 0.0195).
Clinicopathologically, the positivity for p-mTOR was
correlated with the existence of metastasis (p = 0.003),
tumor necrosis (p = 0.0007) and >10 % MIB-1 labeling
index (LI) (p = 0.0038). p-S6RP was correlated with
the existence of metastasis (p = 0.0057), tumor necro-
sis (p = 0.0189), frequent mitosis (p = 0.0377) and higher
AJCC stage (p = 0.0158). p-4EBP was correlated with large
tumor size (p = 0.0316), the existence of metastasis
(p = 0.0014), >10 % MIB-1 LI (p = 0.0095), and higher
AJCC stage (p = 0.0173). HSP90 was correlated with
older (>62 years) patient age (p = 0.034), frequent mitosis
(p = 0.0235) and higher AJCC stage (p = 0.0342).
In the univariate analysis, the positivities for p-Akt, p-
mTOR, p-S6RP and p-4EBP and elevated HSP90 expres-
sion were significant risk factors for a poor prognosis.
The Kaplan-Meier survival curves for OS according to
the IHC results are illustrated in Fig. 3. The multivariateanalysis for immunohistochemical parameters adjusted by
AJCC stage and tumor location indicated that the positivi-
ties for p-Akt, p-mTOR, p-S6RP and HSP90 were poor
prognostic factors for OS (Additional file 2: Table S2).
The Western blotting showed that the level of HSP90
expression in the tumor tissues was higher than that in
the normal tissues
The Western blotting results are illustrated in Additional
file 3: Figure S1. p-Akt, p-mTOR, p-S6RP and p-4EBP
were detected in all tumor samples. The densitometric
analysis demonstrated that immunohistochemically posi-
tive proteins showed higher (>1.0) P-scores, which indi-
cated that the tumor was phosphorylated at a higher
level compared to non-neoplastic tissue. As for PTEN
and HSP90, the expression levels in Western blotting
comparatively corresponded with the immunohisto-
chemical results. The level of HSP90 expression in the
tumor tissues was higher than that in the normal tissues.
17-DMAG caused a decrease in the viability and
invasiveness of the cells and a blockage of the
Akt/ mTOR pathway in UPS
Both cell lines showed no amplification of the MDM2
gene locus by FISH analysis.
The effects of 17-DMAG on the two UPS cell lines are
illustrated in Figs. 4 and 5 and Additional file 4: Figure
S2. HSP90 inhibition significantly decreased the viability
of the FPS-1 and FU-MFH-2 cells in a dose- and time-
dependent manner (p < 0.01) (Fig. 4a). In the Matrigel
Fig. 3 Kaplan-Meier survival curves for overall survival (OS) according to the results of the IHC analysis. Positivities for p-Akt, p-mTOR, p-S6RP,
p-4EBP and HSP90 were correlated with OS by log-rank test. PTEN expression was not correlated with OS
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siveness of both cell lines, FPS-1 (p = 0.009) and FU-
MFH-2 (p = 0.041) (Fig. 4b). In the wound-healing assay,
17-DMAG had no influence on the cell motility in either
cell line (Additional file 4: Figure S2).
The Western blotting showed decreased expressions
of p-Akt, p-mTOR, p-S6RP, p-MEK1/2 and p-ERK1/2 in
both cell lines (Fig. 5). The expression of HSP90 showed
no clear change. The p-Akt expression was decreased at
6 h and at 12 h after the treatment with 17-DMAG, and
the p-mTOR and p-S6RP expressions were decreased at
12 h. This sequential alternation indicated that the in-
hibition of HSP90-Akt binding blocked the Akt/ mTOR
signaling pathway.Fig. 4 17-DMAG suppressed the growth of UPS cells and caused a decreas
a dose- and time-dependent manner. (b) The Matrigel invasion assay show
Error bars = standard deviation.* p < 0.01, ** p < 0.05Discussion
The purpose of the present study was to determine
whether HSP90 could be a therapeutic target against
UPS. We carefully selected the UPSs and observed ele-
vated HSP90 expression and AKT/mTOR pathway acti-
vation by immunohistochemistry and Western blotting.
The multivariate analysis indicated that the positivities
for p-Akt, p-mTOR, p-S6RP and HSP90 were independ-
ent poor-prognosis factors. HSP90 inhibition decreased
the viability and invasiveness of UPS cells and inacti-
vated the AKT/mTOR pathway in vitro.
To conduct our study of UPS, we reclassified tumors
that had been diagnosed as pleomorphic sarcoma. The
basic principle for the diagnosis of soft tissue sarcomase in the invasion of cells. (a) HSP90 inhibition decreased the viability in
ed that 17-DMAG caused a decrease in the invasion of both cell lines.
Fig. 5 17-DMAG reduced the protein expression of the Akt/mTOR pathway. Cell lines were treated with 17-DMAG (0.3 μmol/L) for 6, 12 and 24 h.
The 17-DMAG-induced changes in the activation status of the AKT/mTOR and MAPK pathways were evaluated by Western blotting. Decreased
p-Akt, p-mTOR, p-S6RP, p-MEK1/2 and p-ERK1/2 expressions were observed in both cell lines. The HSP90 expressions showed no clear difference.
The cell lines were also treated with or without 17-DMAG (0.3 μmol/L) diluted in DMSO for 24 h. DMSO had no influence on the status of the
AKT/mTOR or MAPK pathways
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throw tumors into the “wastebasket” of UPS [24, 25].
However, the difference in the morphology remains to
be clarified between UPS with myxoid stroma and a
high-grade component of MFS or between UPS in the
body cavity and sarcomatoid carcinoma [22]. Moreover,
a FISH study is sometimes required for the diagnosis in
addition to the morphology findings.
Amplification of MDM2, the driving genes in 12q13-
15, can frequently be detected by FISH [26, 27]. Repre-
sentative sarcomas with adipocytic differentiation that
show MDM2 gene amplifications are defined as DDLS.
However, a recent study reported that peripheral UPS
with MDM2 gene amplification is considered DDLS
even if there is no well-differentiated liposarcoma area
[23]. We retrieved definitive UPSs, and several poor
prognostic factors were identified including large
(>50 mm) tumor size, deep location, the existence of
tumor necrosis and frequent mitosis. The AJCC stage
was an independent poor-prognosis risk factor for over-
all survival and event-free survival in the multivariate
analysis, supporting the usefulness of the FNCLCC
grades and AJCC staging system.
In clinical samples of reclassified UPSs, we analyzed
the HSP90 expression and Akt/mTOR pathway activa-
tion by immunohistochemistry and Western blotting.
HSP90 is a chaperone interacting with client proteins
that are essential for constitutive cell signaling and adap-
tive response induced by stress [28]. HSP90 also impli-
cates client proteins in activated oncogenesis [29, 30]. It
was revealed that Hsp90 is up-regulated in tumor cells
and transformed cells, and Hsp90 expression was ele-
vated in clinical samples of breast cancer and cholangio-
carcinoma [16, 31, 32]. The present study’s findings
demonstrated that the HSP90 expression was elevated in
approx. 50 % of the UPSs, and this elevated expressionwas an independent poor-prognosis factor in UPS in the
multivariate analysis. The elevated expression of HSP90
was significantly correlated with other poor-prognosis
factors including mitotic figure, FNCLCC grade and
AJCC stage. In addition, the Western blotting analysis
showed that the level of HSP90 expression in the tumor
tissues was higher than that in the non-neoplastic tissue,
although the number of frozen samples was small. This
result suggests that HSP90 could be a candidate target
molecule in the treatment of UPS.
Akt is a serine/threonine kinase activated by PI3K, and
activated AKT initiates a cascade of downstream signal-
ing [33]. The Akt/ mTOR pathway modulates cellular
function in response to extracellular signals and can lead
to tumor initiation and progression [34, 35]. Our group
reported that this pathway was activated in leiomyosar-
comas and malignant peripheral nerve sheath tumors in
approx. 70 and 50 % of the cases, respectively [7, 20].
Lahat et al. reported that 20 % of human UPSs showed
strong expression of p-Akt [36]. The present study’s
findings demonstrated that Akt and downstream mole-
cules were activated in approx. 50 % of the UPSs. This
discrepancy may have occurred because the diagnostic
criteria for UPS were revised by WHO2013 after the
previous report had been published [1, 36]. In our study,
positivities for p-Akt, p-mTOR and p-S6RP were inde-
pendent poor-prognosis factors in the multivariate ana-
lysis, and they were significantly correlated with the
elevated expression of HSP90 and clinicopathological
poor-prognosis factors. These data suggest that the in-
hibition of the Akt/mTOR pathway could have thera-
peutic benefit for the treatment of UPS.
Abnormalities of several molecules could be respon-
sible for the activation of the Akt/mTOR pathway. Some
studies have revealed that gene mutations in PI3KCA or
AKT1 activate the Akt/mTOR pathway [37, 38]. As of
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UPS, to our knowledge. Another molecule involved in
the pathway is PTEN. PTEN antagonizes PI3K function,
and the loss of PTEN increases PI3K-AKT signaling [6].
In the present study, we investigated the status of PTEN
in UPSs, and our immunohistochemical analysis showed
that the loss of PTEN was not correlated with the activa-
tion of the Akt/mTOR pathway.
On the basis of the results of our analysis of clinical
samples, we investigated the effect of an HSP90 inhibitor
on two UPS cell lines. Among biomolecular targets, the
Akt/mTOR pathway presents a well-known target for
molecular therapeutics [39]. A recent large randomized
phase III trial evaluated the effects of an mTOR inhibi-
tor against metastatic sarcomas [40]. However, the result
of this trial was discouraging. This may have occurred
because there is cross-talk between the AKT/mTOR and
MAPK pathways, and MAPK pathway signaling can be
enhanced by mTOR inhibition [41, 42]. Therefore, tar-
geting the Akt/mTOR pathway without enhancing the
MAPK pathway seemed to be more preferable than
using a single-agent mTOR inhibitor in chemotherapy.
In our immunohistochemical study, the elevated expres-
sion of HSP90 was significantly correlated with the acti-
vation of the Akt/mTOR pathway and tended to be
correlated with the activation of the MAPK pathway.
This result suggests that an HSP90 inhibitor could lead
to the blockade of the Akt/mTOR and MAPK pathways
in UPS.
HSP90 inhibition leads to a mechanism-based change
in the expression of specific proteins [4]. HSP90 protects
phosphorylated Akt from dephosphorylation, and the in-
hibition of Akt-Hsp90 binding leads to the dephosphory-
lation and inactivation of Akt [3, 43]. The MAPK
pathway also requires the HSP90-chaperone function for
proper folding and stability [4]. Although HSP90 is
expressed in normal cells, HSP90 derived from tumor
cells has a 100-fold higher binding affinity for HSP90 in-
hibitor compared to HSP90 derived from normal cells,
which indicates the selectivity of HSP90 inhibitors to-
ward tumor cells [44].
We selected 17-DMAG among the several HSP90 in-
hibitors, because 17-DMAG has already been evaluated
in clinical trials for patients with ovarian and breast can-
cer [45, 46]. Our in vitro study yielded evidence that 17-
DMAG decreased the viability and the invasiveness of
UPS cells, and 17-DMAG inactivated the kinase activity
of the Akt/mTOR and MAPK pathways although the
cell motility remained unchanged. Activation of the Akt/
mTOR pathway contributes to increased cell invasive-
ness in prostate cancer and breast cancer [47, 48]. Our
present findings indicate that an Hsp90 inhibitor would
inactivate the Akt-mTOR pathway and subsequently de-
crease the cell invasiveness in UPS. We did not verifythe immediate cause of decreased invasiveness induced
by 17-DMAG. Matrix lysis is one of the sequence of bio-
chemical events during tumor cell invasion, and HSP90
is required for the matrix lysis [49]. An investigation of
the molecular markers involved in the matrix lysis such
as matrix metalloproteinase (MMP) could lead to a bet-
ter understanding of our present findings. Nevertheless,
the HSP90 inhibitor 17-DMAG seems to have a practical
application in targeted therapy against UPS compared
with an mTOR inhibitor.Conclusion
In summary, we conclude that an HSP90 inhibitor could
be a potential treatment option against UPS based on
our clinicopathological assessment, immunohistochemis-
try, Western blotting and an in vitro study using 17-
DMAG on UPS cell lines. Further studies may lead to
the realization of an HSP90 inhibitor in a targeted ther-
apy for UPS.Additional files
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